SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Multiple Sclerosis
This Article
Right arrow Full Text (OnlineFirst PDF)
Right arrow All Versions of this Article:
1352458508097468v1
15/2/272    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Ali, E.
Right arrow Articles by Khoury, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ali, E.
Right arrow Articles by Khoury, S.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Article

Daclizumab in treatment of multiple sclerosis patients

EN Ali*, BC Healy, LA Stazzone, BA Brown, HL Weiner, and SJ Khoury

Partners MS Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; Correspondence to: EN Ali, MD, Partners MS Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. Email: eman_c5@yahoo.com

* To whom correspondence should be addressed.


  Abstract

Background

Daclizumab is a humanized monoclonal antibody (mAb) that blocks the interleukin-2 receptor alpha subunit (IL-2R-alpha chain; CD25) expressed on activated T cells leading to the inhibition of T-cell expansion, thus strongly reduces brain inflammation in patients with multiple sclerosis (MS). Another mechanism is significant expansion of CD56 (bright) natural killer (NK) cells that in turn inhibit T-cell survival.

Objective

At the Partners MS center, we have been using Daclizumab in an open-label fashion in patients who fail first line therapy or non-standard immunosuppressive treatment. Our aim was to assess its safety and tolerability in our patient population.

Key Words: all clinical trials, daclizumab, disease modifying therapies, multiple sclerosis

First published on January 9, 2009, doi:10.1177/1352458508097468

Multiple Sclerosis 2009;15:272.

A more recent version of this article appeared on February 1, 2009

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement